Loading
IMA203 is an experimental TCR-T cell therapy from Immatics US in phase 3 trials for melanoma, aimed at PRAME.
IMA203 is a TCR-T cell therapy developed by Immatics US. Its target is PRAME (the sponsor names PRAME). The sponsor states: An autologous, genetically engineered T-cell receptor (TCR)-T cell therapy directed against PRAME-expressing tumour cells, given as a one-time infusion followed by adjunctive low-dose IL-2 therapy for up to 10 days. ClinicalTrials.gov describes the intervention as: one-time administration of IMA203, and adjunctive therapy with low dose interleukin (IL)-2 for up to 10 days, starting approximately 24 h after IMA203 infusion, optional bridging therapy. It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial, including the phase 3 study NCT06743126 (SUPRAME-ACTengine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous Melanoma), in melanoma. The largest, NCT06743126, plans to enrol 360 participants with primary completion expected 2028-01. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.
An autologous, genetically engineered T-cell receptor (TCR)-T cell therapy directed against PRAME-expressing tumour cells, given as a one-time infusion followed by adjunctive low-dose IL-2 therapy for up to 10 days. Connects to PRAME.
1.IMA203 slips into a pocket on PRAME.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"IMA203" OR ABSTRACT:"IMA203" OR TITLE:"anzutresgene autoleucel" OR ABSTRACT:"anzutresgene autoleucel" OR TITLE:"anzu-cel" OR ABSTRACT:"anzu-cel") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about IMA203, not a curated reading list.
Shares Immatics and the tag pipeline.
Shares Advanced melanoma (unresectable stage III and stage IV), Melanoma and the tag pipeline.
Shares Advanced melanoma (unresectable stage III and stage IV), Melanoma and the tag pipeline.
Shares Advanced melanoma (unresectable stage III and stage IV), Melanoma and the tag pipeline.
Shares Advanced melanoma (unresectable stage III and stage IV), Melanoma and the tag pipeline.
Shares Advanced melanoma (unresectable stage III and stage IV), Melanoma and the tag pipeline.
Shares Advanced melanoma (unresectable stage III and stage IV), Melanoma and the tag pipeline.